Jane Street’s Zevra Therapeutics ZVRA Stock Holding History

Jane Street’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$830K	Buy	57,900 +600	+1%	+$6.67K	﹤0.01%	6921
2026 Q1	$534K	Buy	57,300 +34,000	+146%	+$306K	﹤0.01%	7898
2025 Q4	$209K	Buy	23,300 +1,900	+9%	+$18K	﹤0.01%	9635
2025 Q3	$204K	Sell	21,400 -12,800	-37%	-$128K	﹤0.01%	9657
2025 Q2	$301K	Buy	34,200 +16,200	+90%	+$131K	﹤0.01%	7857
2025 Q1	$135K	Buy	+18,000	New	+$143K	﹤0.01%	8674
2021 Q4	–	Sell	-10,600	Closed	-$99K	–	10918
2021 Q3	$99K	Sell	10,600 -15,200	-59%	-$153K	﹤0.01%	9303
2021 Q2	$331K	Sell	25,800 -64,000	-71%	-$688K	﹤0.01%	7978
2021 Q1	$826K	Buy	+89,800	New	+$784K	﹤0.01%	5832

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street's ZVRA Position: Q2 2026 in Review

Jane Street reduced its Zevra Therapeutics (ZVRA) stake by 90% in Q2 2026, selling an estimated $2.22M and leaving 21,604 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #9151.

Jane Street first reported a position in ZVRA in Q1 2020 and has held it in 15 quarters since. The position peaked at $5.05M in Q4 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Jane Street held 21,604 shares of Zevra Therapeutics worth $310K as of Q2 2026.
Jane Street sold 199,454 Zevra Therapeutics shares in Q2 2026, an estimated $2.22M.
Zevra Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9151 holding.
Jane Street first reported a position in Zevra Therapeutics in Q1 2020 and has held it in 15 quarters since.
Jane Street's Zevra Therapeutics position peaked at $5.05M in Q4 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.